BactiQuant (BACTIQ) Q3 2026 TU earnings summary

Executive summary

• YTD September 2026 revenue was DKK 7.48m, up 36% YoY, driven primarily by recurring sales, especially to Pharma.

• October’s net DKK 9.0m equity raise and repayment of the EIFO loan strengthened liquidity and reduced financial expenses.

Financial highlights

• Revenue reached DKK 7.5m by the end of Q3 2026, up 36% YoY.

• Recurring revenue rose 50% YoY to DKK 4.642m YTD September; it includes consumables for BactiQuant Online and test kits for BactiQuant Mobile Lab.

• After repaying the EIFO loan, cash and cash equivalents were DKK 1.7m at September 30, 2026.

Outlook and guidance

• FY2026 revenue guidance is DKK 10–11m; EBITDA guidance is DKK -6m to -7m, following a revenue clarification and EBITDA upgrade announced November 5.

• Based on forecasts for the remainder of 2026 and 2027, liquidity is expected to be sufficient until mid-2028.